Regulatory & Industry
| 5 min read
The science behind personalized mRNA cancer vaccines is working. Building a different drug for every patient, at scale, is the real fight.
| 4 min read
The first gene therapy for Huntington's disease submitted to the FDA, an mRNA flu vaccine advances to Phase 3 trials, an antibody drug for celiac disease, and more led the news this week.
| 4 min read
Acquiring SupplyRx brings a digital pharmacy card model in-house, extending Inceptua's North American footprint to retail and specialty pharmacies to combat rising overage rates.
| 4 min read
Cell atlases have mapped human biology in unprecedented detail. The harder question for drug discovery is which of those cellular states should change what a program does next.
| 4 min read
Another FDA-approved blood test for Alzheimer’s disease, a large investment in an epilepsy drug, a win for a monoclonal antibody drug, and more led the news this week.
| 3 min read
A logic-gated platform is expanding what's druggable in antibody-drug conjugate development by pairing antigens that cancer cells co-express but normal tissue does not.
| 5 min read
New conjugation chemistries are giving developers greater control over targeting, stability, and payload release.
| 3 min read
Beyond mRNA vaccines, siRNA and antisense therapies are advancing as chemistry, AI, and manufacturing finally keep pace with clinical ambition.
| 4 min read
Immunai has signed three major pharma deals in six months. The reason keeps coming back to the same thing: data that cannot be replicated in a single R&D cycle.
| 6 min read
As in vivo CAR T gains momentum, developers are finding new ways to make ex vivo manufacturing faster, more reproducible, and scalable.
| 4 min read
FDA approvals and complete responses letters, job cuts, a new FDA commissioner nomination, and more led the news this week.
| 6 min read
A new AI analysis of a negative Alzheimer's trial raises questions about whether conventional clinical trials are missing patients who could still benefit from treatment.
